Affiliation:
1. Department of Pharmacy, Henan NO.3 Provincial People’s Hospital, Zhengzhou, China
2. Department of Pharmacy, Weifang People’s Hospital, Weifang, China
3. Department of Pharmacy, Qilu Hospital of Shan Dong University, Jinan, China
4. Department of Renal Endocrinology, The Second Affiliated Hospital of Xi’an Medical University, Xi’an, China.
Abstract
Background:
Research on Jinshuibao (JSB) for chronic renal failure (CRF) is limited, its clinical efficacy on CRF has not been evaluated. Our aim is to systematically evaluate the efficacy of JSB for the treatment of CRF in Chinese patients, and to provide evidence-based medical advice for clinical practice.
Methods:
Randomized controlled trials (RCTs) which compared JSB combined with conventional treatment (CT) with CT alone in CRF were searched in 8 databases including PubMed, EMBASE, Cochrane Library, Web of science, China Biology Medicine disc, Wanfang, Chinese Scientific Journal Database (VIP) and China National Knowledge Infrastructure form inception to March 31, 2023. RevMan5.4 statistical software was used for meta-analysis.
Results:
17 trials involving 1431 cases were identified for meta-analysis. The results showed that total effective rate (relative risk [RR] = 1.25, 95% confidence internal [CI]: 1.17–1.34, P < .00001), creatinine clearance rate (Ccr) (MD = −8.63, 95% CI: −12.42 to −4.84, P < .00001), albumin (Alb) (MD = −2.88, 95% CI: −4.85 to −0.92, P = .004) and hemoglobin (Hb) (MD = −5.88, 95% CI: −7.42 to −4.34, P < .00001) in JSB plus CT were significantly higher than those in CT; while blood urea nitrogen (BUN) (MD = 2.03, 95% CI: 1.27–2.80, P < .00001), serum creatinine (Scr) (MD = 48.23, 95% CI: 31.96–64.49, P < .00001), 24-hour urine protein (24hpro) (MD = 0.19, 95% CI: 0.06–0.31, P = .003), uric acid (UA) (MD = 76.36, 95% CI: 12.40–140.31, P = .02), tumor necrosis factor-α (TNF-α) (MD = 10.74, 95% CI: 5.04–16.45, P = .0002), interleukin-6 (IL-6) (MD = 5.07,95% CI: 1.21–8.92, P = .01), high-sensitivity C-reactive protein (hs-CRP) (MD = 3.74, 95% CI: 0.96–6.52, P = .008) in JSB plus CT were significantly lower than those in CT.
Conclusion:
Combining JSB with CT has a good effect on the treatment of CRF in Chinese people. High-quality RCTs are needed to further confirm the results.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献